Navigation Links
Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab
Date:2/2/2011

ZAR® (gemcitabine HCl for injection) and cisplatin. The same independent DMC recommended that this trial continue because no safety concerns have been observed.

"Patient safety is paramount.  While stopping enrollment in one of the two Phase III trials is disappointing, the SQUIRE Phase III study of necitumumab in lung cancer continues," said Richard Gaynor, M.D., vice president, oncology product development and medical affairs for Lilly.  "Lilly remains committed to developing new medicines that can help treat this devastating disease."

Lilly has contacted all trial investigators to provide detailed information on how to manage individuals enrolled in the trial, and has notified all pertinent regulatory agencies of this decision.

Necitumumab is being developed in a partnership between Lilly and Bristol-Myers Squibb.  The two companies share development costs and any potential commercialization within the U.S., Canada and Japan, while Lilly has exclusive commercialization rights in all other countries.

Notes to Editor

Data Monitoring Committee

A Data Monitoring Committee (DMC) is an independent body consisting of physicians and statisticians.  Their responsibility is to review interim analysis data from clinical trials and make a decision on whether the trial is still set up correctly or needs modifications.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit www.bms.com, or follow us on Twitter at http://twitter.com/bmsnews.

About Lilly Oncology

For more than four decades, Lilly Oncology, a division of Eli Lilly and Company, has been dedicated t
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Lilly, Kowa and Kowa Pharmaceuticals America Announce Co-Promotion and Licensing Agreement
2. Bristol-Myers Squibb Sued for Denying Employees Overtime Pay
3. Bend Research Announces Extension of Drug-Discovery Enablement and Development Services Agreement With Bristol-Myers Squibb
4. Isis Earns $6 Million Milestone Payment From Bristol-Myers Squibb for BMS-PCSK9Rx
5. Top Bristol-Myers Squibb Executive Joins Patton Boggs
6. Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe
7. Bristol-Myers Squibb, New Jersey Childrens Hospital Launch Center for Immune System Disorders & Infectious Diseases Including HIV/AIDS
8. Boston Scientific Begins Clinical Trial Enrollment in China for PROMUS Element™ Everolimus-Eluting Stent
9. Generex to Increase Patient Enrollment of its Phase II Breast Cancer Vaccine Study
10. Boston Scientific Completes Enrollment in EVOLVE Clinical Trial to Evaluate SYNERGY™ Drug-Eluting Coronary Stent
11. Boston Scientific Completes Enrollment in Clinical Trial Evaluating Next-Generation Nitinol Stent to Treat Iliac Artery Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... DIEGO, July 30, 2015  ResMed Inc. (NYSE: ... June 30, 2015.  Revenue for the quarter was $453.1 ... ended June 30, 2014 (a 17 percent increase on ... consistent with the quarter ended June 30, 2014.  Diluted ... with the quarter ended June 30, 2014.  ...
(Date:7/30/2015)... Calif. , July 30, 2015  EP ... /Alcon executives have recently contacted the Company about ... begin as early as Monday, August 3, 2015.  ... quoted as saying that the coming electronic contact ... of dollars over the next several years.  Novartis ...
(Date:7/30/2015)... , July 30, 2015  Unichem Pharmaceuticals ( ... one lot of Hydrochlorothiazide tablets 25 mg 1000-count bottle ... as a precautionary measure due to the identification of ... product. The risk associated with mistakenly ... is the increased probability of experiencing Clopidogrel,s side effects ...
Breaking Medicine Technology:ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets 2
(Date:8/1/2015)... ... August 01, 2015 , ... Tina Wilcoxson, owner of Freeport Maine’s ... given that honor by the National Retail Federation, the largest retail trade association in ... of three Maine business owners to be named as such. According to the NRF’s ...
(Date:8/1/2015)... Dallas, TX (PRWEB) , ... August 01, 2015 , ... ... support for the March4thforWellBeing foundation, making hers the very first small business donation to ... and look beautiful for over thirty years. Her legacy includes a complete line of ...
(Date:7/31/2015)... ... July 31, 2015 , ... When the weather turned hot ... their new type of sod called Leisure Time(TM) zoysia . It's nicknamed LTZ(TM) ... To commemorate introduction of this new type of sod, Super-Sod is giving away red ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... industry players to know in predictive health analytics , Jvion continues to ... The firm creates predictive software that targets patient and population level illness to ...
(Date:7/31/2015)... FL (PRWEB) , ... July 31, 2015 , ... ... announced an important workshop at its new True North Conference Center. The medical ... so that the Jacksonville community may be more aligned in the effort to ...
Breaking Medicine News(10 mins):Health News:Local Retail Advocate Wins National Recognition 2Health News:March4thforWellBeing Foundation Kickoff 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3
... awareness about the,prevalence of Traumatic Brain Injury (TBI) ... Healthcare Alliance has contributed,$50,000 to the Bob Woodruff ... the Department of Defense, current reports suggest that,sixty ... the Global War,on Terror have been impacted by ...
... In recognition of,Diabetes Awareness Month, The ... launched a special,feature, which highlights the ... provides,important information to further the understanding ... can be found at, http://www.healthcentral.com/diabetes/diabetes-awareness-month.html, ,promotes ...
... Nov. 6 Kiadis Pharma,announced today that its ... by the US Food and Drug Administration (FDA) ... Graft versus Host Disease (GvHD),following allogeneic bone marrow ... and anticipated to enter clinical phase III,studies in ...
... concerns about the further underperformance and ... deterioration of shareholder value., ... Taft-Hartley and union health benefit and pension fund trustees ... of Employee Benefit Plans conference. The conference is,considered a ...
... advanced liver disease who did not respond to ... liver enzymes, viral levels, and liver inflammation following ... did not slow or prevent the progression of ... clinical trial, Hepatitis C Antiviral Long-Term Treatment Against ...
... LONG BEACH, Calif., Nov. 6 A class action,lawsuit ... Court,against S&F Management Company, Inc.; S&F Management Company, LLC; ... facilities,around the state [See list by city at end ... his Attorney in Fact, Virginia Boone, on his behalf,and ...
Cached Medicine News:Health News:TriWest Contributes $50,000 to Bob Woodruff Family Fund for Traumatic Brain Injury 2Health News:The HealthCentral Network's MyDiabetesCentral.com Promotes Awareness of Diabetes 2Health News:The HealthCentral Network's MyDiabetesCentral.com Promotes Awareness of Diabetes 3Health News:FDA Grants Kiadis Pharma Lead Product ATIR Orphan Drug Designation 2Health News:FDA Grants Kiadis Pharma Lead Product ATIR Orphan Drug Designation 3Health News:Labor Union Coalition Alerts Industry Analysts About Rite Aid 2Health News:Labor Union Coalition Alerts Industry Analysts About Rite Aid 3Health News:Hepatitis C treatment reduces the virus but serious liver problems may progress 2Health News:Class Action Lawsuit Filed Against 15 California Nursing Homes 2Health News:Class Action Lawsuit Filed Against 15 California Nursing Homes 3
Cementless hip stem revisions offering optimal version setting for each patient. Compatible with modular link ceramic or cobalt chromium femoral heads with up to 4 neck lengths, or the link saddle de...
The proximally modular S-ROM Total Hip System provides custom capability at non-custom prices and is competitive with conventional porous coated systems....
Exactech's AcuMatch C-Series (Cemented Femoral Stem) is designed to provide solutions to the problems which compromise both the short and long term successful outcome of cemented hip arthroplasty....
Severe revision options for the knee and hip...
Medicine Products: